JAN 29, 2016 5:22 PM PST

Blood Pressure Drug May Be Answer to Alzheimer's Disease

WRITTEN BY: Julianne Chiaet
Alzheimer's disease primarily affects individuals over age 65.A drug used to treat high blood pressure could be the answer to treating and preventing Alzheimer’s disease.

Alzheimer’s disease is a progressive degenerative brain disease. It causes cognitive decline and memory loss. In Alzheimer’s disease, damaged cells release too much glutamate, an important neurotransmitter involved in most aspects of brain function. The excess glutamate leads to chronic overexposure to calcium, which in turn speeds up brain cell damage.

Using neuronal cultures, the researchers studied the effects of the high blood pressure medication on the toxic effects of excessive glutamate. The medication, candesartan, is an angiotensin receptor blocker sold under the brand name Atacand.

The researchers found that candesartan prevented neuronal death caused by glutamate. The drug also prevented neuronal inflammation and changes in amyloid metabolism. The latter change is especially important since the buildup of amyloid plaques are a hallmark of the disease. The researchers then compared the gene expression in the cultures to autopsy samples from Alzheimer’s patients that were published in gene databases.
 

"The correlations were impressive. The expression of 471 genes that were altered by excess glutamate in our cultures were also altered in brain autopsy samples from patients who suffered from Alzheimer's disease. Candesartan normalized expression of these genes in our cultures," said study author Abdel G. Elkahloun, from the Comparative Genomics and Cancer Genetics Branch of the National Human Genome Research Institute.

The researchers hypothesize that candesartan and/or other angiotensin receptor blockers have the potential to slow down the progression of Alzheimer’s and prevent or delay its development.
They say their findings support testing candesartan and other angiotensin receptor blockers in controlled clinical studies on patients at early stages of Alzheimer’s.

The research was published online on January 28, 2016, in the journal Alzheimer’s Research and Therapy.

Sources: Journal study Alzheimer’s Research and Therapy, Georgetown University Medical Center press release

 
About the Author
  • Julianne (@JuliChiaet) covers health and medicine for LabRoots. Her work has been published in The Daily Beast, Scientific American, and MailOnline. While primarily a science journalist, she has also covered culture and Japanese organized crime. She is the New York Board Representative for the Asian American Journalists Association (AAJA). • To read more of her writing, or to send her a message, go to Jchiaet.com
You May Also Like
DEC 30, 2020
Drug Discovery & Development
Llama Antibody Prevents Infection by COVID-19
DEC 30, 2020
Llama Antibody Prevents Infection by COVID-19
There's more to llamas than being livestock and hilarious companion animals. They also harbor an immune system capab ...
DEC 30, 2020
Clinical & Molecular DX
Of Mice and Men: Deep Learning Transforms Diagnostics
DEC 30, 2020
Of Mice and Men: Deep Learning Transforms Diagnostics
Medical imaging technologies enable physicians to take a peek under the hood, capturing snapshots of the internal organs ...
DEC 30, 2020
Drug Discovery & Development
Gene Therapy Cures Mice of Deafness
DEC 30, 2020
Gene Therapy Cures Mice of Deafness
Currently, around half a billion people suffer from hearing loss around the world. In about half of these cases, genetic ...
JAN 12, 2021
Microbiology
Connecting Gut Microbes, Diet, and Health
JAN 12, 2021
Connecting Gut Microbes, Diet, and Health
Advances in genetic technologies have revolutionized biomedical research in recent years. One example is the discovery t ...
JAN 13, 2021
Cardiology
Short Bursts of Exercise Boost Markers of Good Health
JAN 13, 2021
Short Bursts of Exercise Boost Markers of Good Health
Exercise is good for our health, but it seems that certain kinds of exercise are more beneficial than others. Recent res ...
JAN 18, 2021
Cell & Molecular Biology
MicroRNAs May be Treatment Targets for Traumatic Brain Injury
JAN 18, 2021
MicroRNAs May be Treatment Targets for Traumatic Brain Injury
Traumatic brain injury, which can happen after a blow to the head, has been called a silent epidemic and is the number o ...
Loading Comments...